WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Xinjiang opens its first museum on Great Wall cultureTestimony in USC case before labor relations board administrative judge could be wrapping upKaty Perry can barely contain her excitement as she gets ready to see Doja Cat headline CoachellaChina, Greece sign deal to boost tourism cooperationBiden, Trump trade barbs during visits to swing state Georgia, U.S.Xinjiang opens its first museum on Great Wall cultureChina, Greece sign deal to boost tourism cooperationRed Sox LF Tyler O'Neill leaves game against Guardians after collision with teammate2024 WNBA Draft: The most anticipated fashion for Monday nightUniversal Beijing Resort to add 2 transportation hubs
2.4722s , 6499.0625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Capsule news portal